ALXN has brilliantly turned their complement inhibitor, Soliris, into a $23 billion market cap company. CLDX may actually have a better complement inhibitor in CDX-1135. Of course, CLDX is years behind ALXN, but ALXN has paved the regulatory roadway. And this shows what an orphan indication drug can be worth.
Shares of Alexion (NASDAQ: ALXN [FREE Stock Trend Analysis]) spiked higher when Bloomberg reported that the pharmaceutical company will be working with Goldman Sachs (NYSE: GS) on a potential takeover by Roche (OTC: RHHBY).
Shares of Alexion jumped as high as $120.48, or 10.2 percent on the news. More than 2.5 million shares have already been traded, compared to the average of 2.03 million.
A previous offer from Roche was rejected, but Alexion will be working with Goldman Sachs in the case that Roche raises their offer to a level the pharmaceutical company finds appealing.